AU Patent

AU2021230289A1 — eIF4E inhibitors and uses thereof

Assigned to Pic Therapeutics Inc · Expires 2022-09-29 · 4y expired

What this patent protects

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

USPTO Abstract

The present invention provides compounds inhibiting elF4E activity and compositions and methods of using thereof.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: AU2021230289A1
Jurisdiction: AU
Classification: —
Expires: 2022-09-29
Drug substance claim: No
Drug product claim: No
Assignee: Pic Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.